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The cellular attachment ofIg molecules to cell surface Fc receptors (FcR)t elicits
a variety offunctional consequences, depending upon the Ig isotype specificity of
the FcR and the cell type that expresses it (1). For example, the binding ofIgG to
FcyRonmacrophagesleadsto theendocytosisand lysosomal degradationofsoluble
immune complexes (2), the phagocytosis ofIgG-coated particles (3), and the secre-
tion ofpotent inflammatory mediators such as prostaglandins, leukotrienes, oxygen
intermediates, and neutral proteases (1, 4).
Three different types ofIgG Fc receptors (FcyR) have been identified on human
blood cells (reviewed in reference 5). FcyR I (CD64) is a 72-kD glycoprotein on
monocytes and macrophages that serves as a high affinity receptor for monomeric
IgG (5, 6). FcyR II (CDw32), a low affinity receptor of 40 kD, is found on a wide
variety ofcell types, including monocytes, platelets, neutrophils, and B cells (5-7).
FcyR III (CD16) is a variably glycosylated, low affinity receptor of 50-70 kD that
is present on neutrophils, eosinophils, NK cells, a subset of T cells, and cultured
monocytes (5, 8, 9). Interestingly, the FcyR III on neutrophils is anchored to the
membrane via a glycosyl-phosphatidylinositol (GPI)linkage(10-13), whereas atrans-
membrane form of FcyR III is identified on NK cells (12, 13). Two different types
ofIgE FcR have been described. The high affinity FccR I, composed ofa tetrameric
complex (a 45-kD a chain, a 33-kD (3 chain, and two 9-kD y chains), is present
on mast cells and basophils (14, 15). The low affinity FceR II (CD23), composed
ofa 45-kD glycoprotein, is present on monocytes, eosinophils, T cells, and B cells
(16, 17). A glycoprotein of -100 kD is involved in the transport ofpolymeric IgA
and IgM across epithelial cells, and thus is denoted as the poly-Ig FcR (18). The
genes encoding all of these FcR, except FceR II, belong to the Ig gene superfamily
(reviewed in references 15 and 19).
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IgA binding to various typesofblood mononuclear cellsin humans has been noted
by several investigators (20 and see review in reference 21). IgA-binding cells were
identified as monocytes and granulocytes in our previous studies (22), and in those
of other laboratories (23, 24). The IgA receptors (IgA-R) on monocytes were shown
to be constitutively expressed (22, 24) and to be involved in IgA-mediated phagocy-
tosis(24). Granulocyte/macrophage CSF (GM-CSF) and granulocyte CSF (G-CSF)
can induce a change from low to high affinity receptors for IgA on granulocytes and
the acquisition of IgA-mediated phagocytic capability (25).
The present studies were designed primarily to examine the biochemical nature
of IgA-R on, monocytes and granulocytes. The results indicate that a heavily
glycosylated protein with an Mr of -60 kD is the FcR for IgA on both of these cell
types and that this FcoeR is distinct from the previously reported FcR .
Materials and Methods
HumanParaproteins.
￿
IgA myeloma proteins, IgAlu and IgAIX, were purified from patients'
sera by salt fractionation, DEAE ion exchange cellulose, and Ultrogel AcA 22 gel filtration
column chromatographies, as previously described (26). The polymeric IgA fraction was shown
by immunoelectrophoresis and SDS-PAGE, under both reducing and nonreducing condi-
tions, to be free of other contaminating serum proteins and to have the appropriate molec-
ular size. Faba and Fca fragments were obtained by cleaving IgAl with IgAl-specific pro-
tease (see review in reference 27). Briefly, polymeric IgAlX (10 mg/ml in 0.05 M phosphate
buffer, pH 7.0) was digested at 37°C for 15 h with crude IgAl protease supernatant from
Hemophilus influenzae (ATCC 35891) (HK 50) at a ratio (vol/vol) of 10:1 (kindly provided by
Dr. J . Mestecky, University of Alabama at Birmingham). After dialyzing against 10 mM
Tris-HCI buffer, pH 8.0, Faba and Fca fragments were separated by DEAE ion exchange
column chromatography using a linear gradient to 0.3 M NaCl. Purity (398%) of the Faba
and polymeric Fca fragments was confirmed by SDS-PAGE analysis under both reducing
and nonreducingconditions. An IgG4X paraprotein was purified as previously described (28),
and shown by SDS-PAGE analysis to be uncontaminated with other Ig isotypes.
Preparation ofAntiidiotypeAntibodies.
￿
The purified IgA and IgG4X myeloma proteins were
used to raise polyclonal antiidiotype (anti-Id) antibodies in goats and rabbits. Removal of
nonidiotypic antibodies by affinity columns, purification of anti-Id antibodies by the corre-
sponding myeloma protein-coupled Sepharose 4B columns, and preparation of F(ab')2 frag-
ments of anti-Id antibodies have been described elsewhere (22, 26, 28). Complete digestion
of IgG molecules into F(ab')2 fragments was established by SDS-PAGE analysis. F(ab')2 frag-
ments of anti-Id antibodies against IgA or IgG4 myeloma proteins were coupled to biotin
as described (22). The idiotype specificity of theseantibodies was confirmed byimmunofluores-
cent staining of the homologous myeloma cells and by lack of staining of nonhomologous
myeloma cells and normal plasma cells.
Cells.
￿
Mononuclear cells isolated from normal blood by Ficoll-Hypaque density gradient
centrifugation were subjected to rosette formation with 2-aminoethylisothiouronium bro-
mide-treated SRBC (29). Monocytes were enriched from the T cell-depleted fraction by
adherence to plastic tissue culture dishes for 1 h at 37°C and recovered by incubation with
PBS containing 5% FCS for 30 min on ice and gentle scraping with a rubber policeman.
Cells in these preparations were predominantly reactive (70-80%) with the Leu-Ml (CD15)
mAb (30). Granulocytes were isolated from the RBC pellet by differential sedimentation in
1.5% dextran in PBS (31). All reagents for granulocyte preparation were made byusing pyrogen-
free distilled water containing soybean trypsin inhibitor (1 mg/ml; Sigma Chemical Co., St.
Louis, MO) to avoid cell aggregation. This fraction contained >95% granulocytes by mor-
phological criteria.
Two human myelomonocytic cell lines, U937 (32) and PLB 985 (33), were obtained from
the American Type Culture Collection (Rockville, MD) and Dr. T. A. Rado (University of
Alabama at Birmingham), respectively. For the induction of IgA-R expression, cells wereMONTEIRO ET AL.
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stimulated with varying concentrations ofPMA (Sigma Chemical Co.), rIFN-'y (Amgen Bio-
logicals, Thousand Oaks, CA), rIFN-u (RocheTakeda Co., Tokyo, Japan), rIFN-a (Kyowa
Hakko, Tokyo, Japan), rIL-1 /3 (Amgen Biologicals), or rIL-4 (Immunex, Seattle, WA). Cells
were also cultured with varying doses ofpolymeric IgAla for 0.5-18 h. In some experiments,
afterpreincubation with polymeric IgAlxfor 18 h, the washed cells were cultured in the medium
without IgA for various periods.
Immunofiuorescence Analysis of Cells.
￿
For the detection of IgA-R, a previously established
immunofluorescence assay was performed (22). Briefly, cells (5 x 105) were incubated for
15-60min at 4°C with 10,ulofpurified polymeric IgA (0.5 mg/ml) and 10 JAI ofbiotin-labeled
F(ab')2 fragments of the appropriate goat anti-Id antibodies (0.5 mg/ml) in PBS containing
0.01% CaC12, 0.01% MgC12, 1% BSA, and 0.05% sodium azide. After washing,
phycoerythrin-labeled streptavidin (Becton Dickinson & Co., Mountain View, CA) was used
as a developing reagent. Unrelated IgA myelomas were used as controls. Cells were analyzed
by flow immunocytofluorometry using a FACScan instrument (Becton Dickinson & Co.).
In some experiments, the following mouse mAbs and their isotype-matched control mAbs
were used: (a) 32.2 (yla isotype) and IV.3 (y2b) mAbs specific for FcyR I and II, respectively,
kindly provided by Dr. M. Fanger (Dartmouth Medical School, Hanover, NH) and Dr. C . L.
Anderson (Ohio State University, Columbus, OH) (34, 35); (b) 3G8 ('Y1K) mAb specific for
FcyR III, a generous gift of Dr. J. C. Unkeless (Mt. Sinai Medical School, NY) (8); and
(c) IA10 (-y2aK) mAb specific for decay-accelerating factor (DAF; CD55), a kind gift of Dr.
V. Nussenzweig (New York University School of Medicine, NY) (36). FITC-labeled goat
antibodies specific for mouse Ig (Southern Biotechnology Associates, Birmingham, AL) were
used as the developing reagent.
Immunoprecipitation of Iodinated Membrane Proteins.
￿
2-3 x 107 viable cells were extensively
washed in PBS, labeled with Na'25I (1 mCi; Amersham Corp., Arlington Heights, IL) by
the lactoperoxidase method (37), and lysed in the following solutions: (a) 0.5% NP-40 in
PBS containing 0.01% CaC12, 0.01% MgC12, 0.02% sodium azide, 0.01% soybean trypsin
inhibitor, leupeptin (10 Rg/ml), pepstatin A (1 wg/ml), chymostatin (2 Wg/ml), antipain (2
,ug/ml), 10 mM benzamidine hydrochloride, 50 mM e-amino-caproic acid, 20 mM iodo-
acetamide, and 1 mM PMSF, for monocytes and U937 cells; and (b) 0.5% NP-40 in PBS
containing 0.01% CaC12, 0.01% MgC12, 0.02% sodium azide, 1% aprotinin, 1 mM di-
isopropylfluorophosphate, 5 mM iodoacetamide, and 1 mM PMSF for granulocytes. In some
experiments, 0.3% CHAPS or 1% digitonin was used instead of NP-40. After centrifuga-
tion, the cell lysates were first incubated with Sepharose 4B coupled with normal human IgG
and with normal goat IgG (5 mg/ml of gel) for 2 h at 4'C with rotation. This preclearance
procedure was repeated seven more times, and lysates were then incubated with 10,ulof poly-
meric myeloma IgA (1 mg/ml) plus 20 td of Sepharose 4B coupled with F(ab')2 anti-Id anti-
body (2 mg/ml of gel) for 2 h (for granulocytes) or overnight (for monocytes and U937 cells)
at 4°C. After washing extensively with lysis buffer, the bound molecules were dissociated
by addition of Laemmli's sample buffer (38), and resolved by SDS-PAGE analysis using 10%
acrylamide. Molecular weight markers are lysozyme, 14,400; soybean trypsin inhibitor, 21,500;
carbonic anhydrase, 31,000; OVA, 42,699; BSA, 66,200; and phosphorylase b, 97,400 (Bio-
Rad Laboratories, Richmond, CA). In some experiments, IgG4A myeloma plus its rabbit
F(ab')2 anti-Id antibody-coupled Sepharose 4B and 3G8 mAb-coupled Sepharose 4B were
used to detect FcyR I and III, respectively. For neuraminidase treatment, IgA-bound mole-
cules were first eluted from beads with 0.5 M acetic acid containing 0.5% NP-40, the pH
was adjusted to 7.0 by addition of 2 M Tris, and then the molecules were incubated at 37°C
for 2 h in the presence of 1 mM PMSF, I% aprotinin, and neuraminidase (50 U/ml; Gibco
Laboratories, Grand Island, NY). For glycosidase digestion (39), the IgA-bound molecules
were dissociated by incubation for 20 min at 80°C in the presence of0.5% SDS-0.1 M 2-ME,
diluted into 0.17% SDS, 33 mM 2-ME, 0.2 M sodium phosphate (pH 8.6), 10 mM 1,10-
phenanthroline hydrate, and 1.25% NP-40, and incubated overnight at 37'C with N-glycanase
(Genzyme, Boston, MA) at 10-40 U/ml. Digested and undigested control materials were
precipitated in acetone at -20'C, washed in 70% ethanol, dried, and resuspended in Laemmli's
sample buffer. For two-dimensional gel analysis, the IgA-bound molecules were resuspended
in 9.5 M Urea/2% Triton X-100/5% 2-ME, and separated first in tube gels containing a 4:1600
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mixture of 5/7 ampholite and 3/10 ampholite, and then run in slabs of SDS-PAGE according
to the method of O'Farrell et al. (40).
Enzyme Treatment ofCells.
￿
Granulocytes, monocytes, and PMA-activated U937 cells (5 x
106/ml) were incubated for 45 min at 37°C with HBSS containing various amounts of one
ofthe followingenzymes: trypsinTPCK (Sigma Chemical Co.), pronase (Calbiochem-Behring
Corp., LaJolla, CA), and neuraminidase (Gibco Laboratories). For GPI-anchorexperiments,
cells were resuspended in HBSS, pH 7.4, containing 10 mM Hepes and 0.1% BSA, and treated
for 45 min at 37°C with phosphatidylinositol-specific phospholipase C (PI-PLC; from Ba-
cillus thuringiensis; enzyme activity, 0.35 uM/min/ml), a generous gift of Dr. M. G. Low
(Columbia University, NY) (41). After treatment, cells were washed with PBS containing
5% FCS, overlaid on Ficoll-Hypaque to eliminate dead cells, stained for surface IgA-R and
other antigens, and analyzed by flow immunocytometry.
Results
Expression of IgA-R and IgG-R by Blood Monocytes, Granulocytes, and Related Cell
Lines. We have previously demonstrated by immunofluorescence that freshly iso-
lated blood monocytes constitutively express class-specific receptors for both IgAl
and IgA2 molecules (22). To determine whether the same or distinctive subpopula-
tions of monocytes and granulocytes express IgG-R and IgA-R, two-color im-
munofluorescence analysis was performed. A combination of the polymeric IgA-
myeloma protein plus the corresponding biotinylated anti-Id antibody was used for
the detection of IgA-R, and mAbs specific for each FcyR (32.2, IV.3, or 3G8) for
the simultaneous detection of FcyR I, II, or III . As shown in Fig. 1, monocytes ex-
pressed the IgA-R and the FcyR I and II, but not the FcyR III. Granulocytes ex-
pressed the IgA-R at a relatively lower level. All of the IgA-R-bearing granulocytes
expressed FcyR II and III, but not FcyR I.
Two myelomonocytic cell lines (U937 and PLB 985) were also examined for the
expression of IgA-R . Both the U937 (see below) and the PLB 985 cell lines exhibited
IgA binding at relatively low levels. The IgA-R on these cell lines was not specific
for a particularIgA myeloma protein, since binding assays using two different IgAl,
as well as an IgA2, myelomas yielded the same results. Both cell lines displayed con-
stitutive expression ofboth FcyR I and II, but not of FcyR III. The results indicate
a
a
Monocytes
Granulocytes
FcyR 1
￿
FcyR II
￿
FcyR III
FIGURE 1.
￿
Immunofluorescence analysis of
IgA-R and IgG-R expression by human
monocytes andgranulocytes. Cellswere first
incubated with an IgA immune complex
(polymeric IgAllc myeloma plus its biotin-
ylated F(ab')2 anti-Id antibody) and phyco-
erythrin-labeled streptavidin, as describedin
MaterialsandMethods. Thecells were prein-
cubated with human serum IgG (10 mg/ml)
in order to mask the binding sites of FcyR,
andthen counterstained forthe FcyR expres-
sion by usingintact mAbs specific for a non-
binding site epitope ofeach FcyR (0.05 mg/
ml):32.2 mAbforFcyR I, IV.3 mAbforFcyR
II,and3G8mAb forFcyR III. FITC-labeled
goat anti-mouse Ig antibody without cross-
reactivity to human Igs was used as a de-
veloping reagent. Nonhomologous IgAl my-
eloma and isotype-matched mousemyeloma
proteins were used as controls.that both monocytes and granulocytes express IgA-R, while each expresses a dis-
tinctive array of FcyR .
Regulation ofIgA-R Expression by U937 Cells .
￿
To examine fordifferences in the regu-
lation of IgA-R and FcyR expression, U937 cells were examined before and after
treatment with various stimuli . IgA-R expression wasupregulated two- to three-fold
after stimulation withPMA (Fig . 2). The increased expression wasPMA dose de-
pendent with the maximal response occurring at a concentration of ti 10-1 M. In-
creased IgA-R expression was observed as early as 12 h afterPMA stimulation, and
the maximal response was obtained at 18 h (Fig . 3). In contrast, the levels of FcyR
I and FcyR II expression were unaffected by stimulation with PMA over a wide
range of concentrations. PMA did not induce the expression of FcyR III (CD16)
that could be detected by the 3G8 mAb. The same results were obtained with an-
other myelomonocytic cell line, PLB 985 cells (data not shown) .
rIFN-y enhanced the expression ofFcyR I ina dose-dependent manner, as noted
previously (42), whereas rIFN-a, -(3, and -y had no effect on IgA-R expression by
U937 cells (Fig. 4; the results with rIFN-et and -0 arenotshown) . No rIFN-y-induced
change in the expression ofFcyR II was observed, and FcyR III expression was not
E
Z
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FIGURE 2.
￿
The effect ofPMA stimulation
on expression of IgA-Rand FccRs by U937
cells . Cells were incubated for 18 h with var-
ious doses ofPMA, washed, and stained for
IgA-R (/), FcyR I (®), and FcyR II (®),
as described in Fig. 1 . The stained cells were
analyzed by flow immunocytometry . Results
were expressed as themean fluorescence in-
tensity, whichwas estimated by: (x ofstaining
ofPMA-treated cells - xofbackground con-
trol staining of PMA-treated cells)/(x of
stainingofnontreated cells - x ofbackground
control staining ofnontreated cells) ; in which
x indicates the computer mean fluorescence
intensity value of each FAGS profile .
FIGURE 3 .
￿
Time course ofPMA-induced IgA-R
expression by U937 cells . Cells were incubated
for varying time intervals with PMA(10-7 M),
washed, and stained for IgA-R, as described in
Fig. 1 . IgA-R expression wasunaltered over the
first 6-h period (0.5-, 1-, 2-, and 6-h profiles are
not shown) .602
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induced . Neither rIL-lei nor HL-4 (10-1,000 U/ml) affected IgA-R expression (data
not shown) .
Polymeric IgA promptly induced increased IgA-R expression by U937 cells in
a dose-dependent manner (Fig . 5) . This upregulation was dependent on the con-
tinuous presence of IgA; removal of polymeric IgA resulted in a time-dependent
decline of IgA-binding capability. The cellular expression of Fc-YR I and II did not
change during the course of these experiments .
The results reveal that PMA and polymeric IgA induce enhanced expression of
IgA-R by U937 cells, but do not affect Fc-yR expression . Conversely, IgA-R expres-
sion is unaffected by IFN- ,y, which enhances Fc-yR I expression .
Characterization ofIgA-R Molecules.
￿
To determine the molecular nature ofthe IgA-R,
iodinated IgA-binding proteins from the cell surface of granulocytes, monocytes,
and the U937 cell line were examined by SDS-PAGE . A broad band with an ap-
parent M, of 60 ± 3 kD (mean ± SD from 21 experiments) was specifically precipi-
E
E
z
FIGURE 4 .
￿
Recombinant IFN-'y stimulation
enhances FcyR I, but not IgA-R, expression
by U937 cells . Cells were incubated for 18 h
with various doses of rIFN-y, washed, and
stained for IgA-R (/), FcryR I (®), andFcyR
II (M), as described in Fig. 1 . Mean fluores-
cence intensitywas calculated as described in
Fig. 2 .
Log Fluorescence
￿
PolymericIgA(mymi)
FIGURE 5 .
￿
Polymeric IgA induces upregulation of IgA-R expression by U937 cells. (A)U937
cells were cultured for varying intervals (0.5, 1, 3, 6, 12, and 18 h) with polymeric IgAla at 0.5
mg/ml, washed, and stained with the corresponding anti-Id antibody. In this experiment, an
anti-Id antibody specific for another IgA myeloma(IgAIX) was used as a negative control . (B)
Cells were incubated for 1 h with twofold serial dilutions ofpolymericIgAlK (2 .5 mg/ml), washed,
and stained with the corresponding anti-Id antibody. Mean fluorescence intensitywas calculated
as described in Fig. 2 .MONTEIRO ET AL .
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tated from all three cell sources by an IgA immune complex consisting of a poly-
meric IgA1u myeloma and F(ab')2 fragments of anti-Id antibodies (Fig . 6, lanes 4,
6, 8, and 13) . In agreement with the immunofluorescence results, PMA-activated
U937 cellsyielded amore intense60-kD band than didtheunstimulated U937 cells
(Fig . 6, lane 8vs . 13) . The same molecular mass estimate was obtained under both
reducing and nonreducing conditions . When the radiolabeled cellswere solubilized
with 0.3% CHAPS or 1% digitonin, mild detergents that can lyse cells without dis-
rupting noncovalently associated complexes of membrane proteins, no additional
bands were coprecipitated with the60-kD protein (datanot shown) . The specificity
of the 60-kD protein for IgA was indicated by the following observations : (a) F(ab')2
fragments of anti-Id antibodies (goat and rabbit) plus the Id IgA1u myeloma re-
vealed the 60-kD protein, whereas anti-Id alone did not precipitate the molecule
(Fig . 6; compare with Fig . 8); (b)another IgA myeloma (IgAIX)and itscorresponding
anti-Id antibody also precipitated the same 60-kD molecule ; (c) monomeric IgAlK
and an IgA2X both precipitated the molecule ; and (d) after removal of FcyRs by
preclearance with normal IgG and IgG4 myeloma or with mAbs specific for FcyR
I, II, and III, the distinctive 60-kD IgA-R was still identified (see Fig . 6, lanes 1
and 2 vs . 4, and lanes 9-11 vs . 13).
In two-dimensional gel analysis, the IgA-R isolated from P-MA-activated U937
cells was resolved into a series of spots with isoelectric points (pI) ranging from 4.5
to 5.6 (Fig. 7 A) . Neuraminidase treatment reduced the size of the IgA-R to 54 kD,
which was distributed in a two-dimensional gel as five major spots with pI between
5.8 and 6.6 (Fig . 7 B) . This patternwasvery different from the 72-kD Fc-yR I, which
was resolved into ti 10 spots with pI between 6.0 and 7 .0 before, and into basic end
spots with pI >7 .0 after neuraminidase treatment (data not shown), consistent with
the results reported by others (6, 34).
FIGURE 6. SDS-PAGE anal-
ysis of IgA-Rmolecules . Gran-
ulocytes andmonocytes freshly
purified from peripheral blood,
and U937 cells activated
without or with 10-7MPMA
(N3 x 10 7 cells each) were la-
beled with 1 mCi of Na l"I and
solubilized with 0.5% NP-40
buffer, as described in Materials
and Methods. The radiolabeled
membrane lysates were pre-
cleared several times with Seph-
arose 4B beads to which 3G8
anti-FcyR III mAb (lane 1),
normal humanIgG (lane 9), or
rabbit F(ab')2 anti-Id antibody
plus its corresponding Id, IgG4Xmyeloma protein (lane 10) were coupled . After removal of FcyRs (see
lanes 2and 11), the precleared lysates were divided into two portions. One was used as a negative con-
trol by incubating with goat F(ab')2 anti-Id-coupled beads (lanes 3, 5, 7, and 12) . The other portion
was used to assay for IgA-Rby incubating with theIgA immune complex: goat F(ab')2 anti-Id-coupled
beads plus its homologous polymeric IgAl K(lanes 4, 6, 8, and13). Thebound proteins were dissociated
by Laemmli'ssample buffer andanalyzed by SDS-10% PAGE under both nonreducing(data not shown)
andreducing conditions . Mobilities and sizes (kD) ofstandard proteins are indicated . The arrows indi-
cate the 60-kD IgA-R molecule.604
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FIGURE 7 .
￿
Two-dimensional (IEF andSDS) gel
electrophoresis analysisof IgA-R . IgA-R isolated
from radiolabeled membrane lysate of PMA-
activated U937 cells (5 x 10 7 cells) was eluted
from beads and divided into two portions. One
(A) received buffer, and the other (B) received
neuraminidase (50 U/ml), as described in
Materials and Methods . The samples were
precipitated with acetone, resuspended, and sepa-
rated first by IEF, and then by SDS-10% PAGE .
Direct pH measurements were made with sliced
control gels resuspended in distilled water. Mo-
bilities and sizes (kD) of standard proteins are
indicated .
When thepurified IgA-R from granulocytesand activatedU937 cells wasdigested
with an excess of N-glycanase (40 U/ml ; reference 43), the 60-kD IgA-R from both
cell sources was resolved into two bands with apparent M, of 32 and 36 kD (Fig.
8, lanes2 and 5vs . 3and 6) . Therelative intensities of these twobandswere constant
after digestion with varyingconcentrations ofN-glycanase(10-40 U/ml), suggesting
that the larger36-kDbandwasnotthe result ofincomplete deglycosylation . In agree-
ment with previous reports (9, 13, 43-46), N-glycanase treatment of granulocyte
FcyR III and U937 FcyR I resolved into two bands of 23 and 28 kD (Fig . 8, lane
8 vs . 9) and into a single band of -40 kD, respectively (data not shown).
These findings demonstrate that the IgA-Ron granulocytes, monocytes, and U937
cells: (a) migrates asa broad band of-60kDunder both reducingand nonreducing
conditions ; (b) appearsidenticalin sizeon both cell types ; (c) is distinctivefrom IgG-R
(FcyR 1, II, and III) ; (d) exhibits heterogenous charge (pI, 4.5-5.6); and (e) is com-
posed of two protein cores (32 and 36 kD) with multiple N-linked carbohydrate
moieties .
Determination of Regions Involved in IgA Binding .
￿
A polymeric IgAIA molecule,
its purified Fabct and Fca fragments, and other classes of Ig were used as inhibitorsMONTEIRO ET AL .
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FIGURE 8.
￿
Glycoprotein nature ofIgA-Rmole-
cules. 3 x 10 7 PMA-activated U937 cells (lanes
1-3) and freshly isolated granulocytes (lanes 4-9)
were labeled and solubilized as described in Fig .
6 . The IgA-R and FcyR III were isolated from
theradiolabeled membrane lysates and incubated
in the presence (+) or absence (-) ofN-glycanase
(40U/ml), asdescribed in MaterialsandMethods.
The samples were precipitated with acetone,
resuspended, andanalyzed by SDS-107o PAGE .
Lanes I and 4, rabbit F(ab')2 anti-Id alone ; lanes
2, 3, 5, and 6, polymeric IgAl plus rabbit F(ab)2
anti-Id ; lane 7, controlmouse IgGlK ; lanes8and
9, 3G8 anti-FeyR III mAb . Mobilities and size
(kD) of standard proteins are indicated .
in the immunofluorescence assay for IgA binding. Both the intact IgAIA and the
polymericFca fragments inhibitedbinding ofthe IgAlK myeloma to activated U937
cells in a dose-dependent manner, whereas Faba fragments, other classes of mye-
lomas (IgG, IgM, IgD), and normal serum IgG did not (Fig . 9 A) . The minimal
inhibition notedwith the highest dose ofFaba (10 mg/ml) probably reflects theminor
contamination ofFca fragments (1-27o) detected by SDS-PAGE densitometry analysis.
To determine if the Fc portion of the IgA molecule is the specific ligand for the
60-kD cell surface molecule, the same panel of inhibitor proteins was used in the
immunoisolation assay for IgA-R molecules on activated U937 cells. Addition of
a 100-fold excess ofnonhomologous IgAla or its polymeric Fca fragments blocked
completely the binding of the 60-kD IgA-R molecules to beads coated with the
IgAIK/anti-Id complex (Fig . 9 B, lanes 2 vs . 3 and 5) . In contrast, Faba fragments
did not affect the IgA-R binding(Fig . 9, lane 4) . More direct evidencewasobtained
by incubation of the 60-kD protein bound to the IgAlK/anti-Id immune complex
with or withoutH . influenzae-derived IgAl protease, which cuts the hinge region
ofal H chains . The IgAl-protease treatment released the 60-kD molecule from the
beads into the supernatant (Fig. 9 B, lanes 7 and 9), whereas the untreated control
did not (lanes 6and 8) . These resultsdemonstratethat the IgAbinding to the 60-kD
glycoprotein is via the Fca portion .
Enzyme Susceptibility of the Cell Surface IgA-R .
￿
To determine whether the IgA-R
molecule is anchored to the cell membrane through a GPI linkage, as is the case
forthe FcyR IIIon neutrophils (10-13, 46), IgA-Rexpression on granulocytes, mono-
cytes, and activated U937 cells was examined before and after treatment with PI-
PLC. Both DAF (47) and FcyR III were removed from the cell surface of granulo-
cytesby PI-PLC treatment as expected, but the IgA-R and FcyR 11 were unaffected606
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FIGURE 9.
￿
Specificity of IgA receptors
and determination of the regions of IgA
molecule involved in binding. (A) PMA-
activated U937 cells (5 x 10 5) were in-
cubated for 30 min at 4°C with various
inhibitor proteins : nonhomologous poly-
meric IgAIX ("), its polymeric Fca frag-
ment (A), its Faba fragment (A), IgMlc
myeloma (+), IgDX myeloma (O), or
IgG4X myeloma plus normal serum IgG
((]) . The cells were then incubated with
polymericIgAlu (0.25mg/ml)and its cor-
responding biotinylated F(ab')2.y anti-Id
antibody (0.25 mg/ml) for an additional
30 min at 4°C. The cell-bound IgAwas
identified by phycoerythrin-labeled strep-
tavidin. By calculating the mean fluores-
cence intensity of IgAbinding over back-
ground, a numerical estimate of the
relativeefficiencyofinhibition couldbe ob-
tained for the different preparations, as de-
scribed elsewhere (22). (B)After preclear-
ing Fc-yRs, the radiolabeled membrane
lysates from PMA-activated U937 cells
(5 x 10' cells) were divided into two por-
tions . One portion was further aliquoted
into five tubes that contained goat F(ab')2
anti-Id-coupled beads without (lane 1) or
with 10 F+g of the corresponding polymeric IgAla (lanes 2-5) in the presence of 100-fold excess ofinhibi-
tors : polymeric IgAIX (lane 3), its Faba fragment (lane 4), and its polymeric Fca fragment (lane 5) .
The other portion was incubated with IgAln/ anti-Id complex beads, washed, and incubated without
(lane or with H . influenzae-derived IgAl protease for 1 h at 37°C (lane 7). The supernatants were
recovered from both aliquots (lanes 8and 9, respectively), followed by acetone precipitation . Allbound
or released materials were dissolved in Laemmli's sample buffer and analyzed by SDS- 10% PAGE.
The arrow indicates the 60-kD IgA-R molecule.
by this treatment (Table I) . Similar results were obtained using freshly purified mono-
cytes and activated U937 cells : the IgA-R, FcyR I, and FcyR II were unaffected
by PI-PLC treatment, whereas the DAF was removed . Thus, unlike FcyR III, the
IgA-R is not GPI anchored on either granulocytes or monocyte/macrophages .
The effects of proteolytic and glycolytic enzymeson IgA-R expression were exam-
ined by treatment of the cells with trypsinTPCK, pronase, or neuraminidase. Un-
like DAF, the IgA-R appeared to be trypsin resistant on all cell sources (Table I) .
This was true even with ahigh dose of trypsin (5 mg/ml ; data not shown) . All FcyRs,
regardless of cellular origin, were also trypsin resistant, as has been noted previ-
ously (44, 45) . By contrast, the IgA-R, FcyR III, andDAF were pronase sensitive,
whilethe FcyR I and II were relatively pronase resistant . Interestingly, neuraminidase-
mediated removal of sialic acid residues consistently resulted in a three- to fivefold
increase in IgA binding, whereas the expression ofFcyR and DAF was either only
slightly increased or unaltered .
Discussion
While much has been learned about the biological and molecular characteristics
ofFcyR and FccR during the last decade, relatively little is known about the molec-MONTEIRO ET AL.
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TABLE I
Enzyme Treatment of Cell Surface Receptors
Cells (5 x 106 each) were treated with 1 nil of 0.35 nM PI-PLC, 0.1 % trypsin-
TPCK, 0.1 % pronase, or neuraminidase (50 U/ml) for 45 min at 37°C. Treat-
ed and untreated cells were stained for IgA-R (polymeric IgA myeloma plus anti-
Id), FcyR I (32 .2 mAb), FcyR II (IV.3 mAb), FcyR III (3G8 mAb), and DAF
(IA10 mAb), as described in Materials and Methods. The mean fluorescence
intensity was estimated as described in Fig. 2.
ular nature ofthe IgA-R that has been identified by immunofluorescence on human
monocytes and granulocytes (22-24). The results of the present experiments indi-
cate that freshly isolated monocytes and granulocytes expressboth IgA-R andFcyR,
as do their corresponding cell lines (U937 and PLB 985). The IgA-R appears to
be a glycoprotein of -60 kD on both cell types. The binding of IgA to the 60-kD
molecule is mediated specifically by the Fca portion of IgA molecules, thus iden-
tifyingthis molecule as an FcotR on both granulocytes and monocyte/macrophages.
The simultaneous expression of both FcciR and FcyR by these myeloid lineage
cells is consistent with other evidence indicating that a given cell can express more
than one type of FcR (see reviews in references 5 and 21). Monocytes, thus, can
express the FcyR I and II, FCER II, and FcaR. However, our results indicate that
each FcR maybehave differently in response to the same stimulus, suggesting unique
regulatory elements for each receptor. Treatment of U937 cells with PMA or poly-
meric IgA enhanced the expression of IgA-R, but not of FcyR I and II, whereas
rIFN-y selectively inducedFcyR I upregulation. The kinetics of FcceR upregulation
induced by PMA and polymericIgA stimulation differ. Enhanced FcCIR expression
occurred -12 h after PMA stimulation and within 30 min after exposure to poly-
mericIgA, implying differentinduction mechanisms for these twostimuli. Moreover,
removal of the polymeric IgA stimulus resulted in an immediate decline in IgA-R
expression, as is characteristic of ligand-induced FcR expression (21, 48-50). How-
ever, it should be noted that FcaR expression on monocytes appears to be constitu-
tive even in IgA-deficient individuals (22).
Cell type
and receptors
Mean
PI-PLC
fluorescence
Trypsin
intensity after
Pronase
treatment with:
Neuraminidase
Granulocytes
IgA-R 1 .5 0.9 0.3 5.2
FcyR II 1 .3 1 .2 0.7 2.3
FcyR III 0.2 1 .3 0.1 2.2
DAF 0.2 0 .3 0.05 1 .4
Monocytes
IgA-R 1 .0 1 .0 0.2 3.6
FcyR I 1 .5 0.8 0.8 2.2
FcyR II 1 .0 0.8 0.7 1 .4
DAF 0.15 0.4 0.3 1 .0
PMA-activated
U937 cells
IgA-R 1 .1 1 .0 0.3 5.1
FcyR I 0.9 0.8 0.6 1 .4
FcyR II 0.9 0.8 0.7 1 .3
DAF 0.3 0.3 0.05 0.9608
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Weisbart et al. (25) have reported that hematopoietic factors, GM-CSF andG-CSF,
can affect granulocytes to reduce the numbers of IgA-binding sites while increasing
the affinity of the remaining receptors. It remains unresolved whether this change
from low to high affinity IgA-R on granulocytes is due to a modification of a pre-
existing, lowaffinity IgA-R or to the appearance of anotherreceptor with high affinity
for IgA. It will thus be of interest to determine whether the 60-kD FcaR described
here is altered by CSF stimulation.
Severalreports indicate that theFc portionof a H chains can bind either noncova-
lently or covalently to severalplasma proteins, including albumin(67 kD), amylase
(55 kD), al-antitrypsin (58 kD), aspartate aminotransferase (-40 kD), lactate de-
hydrogenase (34kD), and al-microglobulin or protein HC (31 and 90 kD) (51-59).
Thepreparations of IgA myelomaproteins used in this studydid not contain detect-
able amounts of these proteins, and the a H chains were of normal size by SDS-
PAGE analysis, further indicating the absence of such binding factors. The possi-
bility that plasma proteins may bind first to the cell surface and then to the IgA
myelomaproteins is excluded by the finding that the IgA-R in CHAPS-, digitonin-,
and NP-40-solubilized membrane preparations exhibited the same M, with no evi-
dence of associated proteins under both reducing and nonreducing conditions.
Other types of proteins are involved in IgA binding by certain cell types. The
poly-Ig-R of -100 kD is expressed at the basolateral surface of intestinal and glan-
dular epithelial cells and functions in the transcellular transport of polymeric IgA
and IgM (18). Antisera against secretory component, the released protein of the
poly-Ig-R, appear to inhibit thebindingofIgA-coated erythrocytes by murine spleen
cells, suggesting the existenceof poly-Ig-R on spleen cells(60). However, it has been
reported recently that no poly-Ig-R mRNA is expressed by human spleen cells(61).
The -45-kD asialoglycoprotein receptor expressedby hepatocytes can mediate the
endocytosis of desialylated plasma glycoproteins (62). Recent studies indicate that
polymeric IgAl can bind to this receptor via the 0-linked oligosaccharides present
on the hinge region of IgAl molecules (63). However, the FcUR described here is
clearly different from either of these receptors.
While IgA-binding has been demonstrated for certain blood cells in both mice
and humans (see reviews in references 21 and 64), the biochemical nature of a pos-
sible IgA-R on blood cells has been elusive in both species. Albrechtsen et al. (65)
have recently reported an IgA-binding molecule on human granulocytes that is resolved
as abroad band ranging from 55 to 60 kD. They were unable to ascertain whether
this IgA-binding molecule differed from the FcyR III, which has a similar molec-
ular size. The present resultsextend this previous analysis by showing that the-60-
kD IgA-bindingmolecule present on both granulocytes and monocyte/macrophages
is an FcaR that is distinct from the other types of FcR that have been described.
The class-specific binding of IgA to the 60-kD receptor is mediated by the Fc por-
tion of IgA, suggesting that CH2 and/or CH3 is involved in binding to the FcCIR.
The FcuR molecules were found to be heterogenously charged with pl of 4.5-5 .6.
Neuraminidase treatment reduced the FccYR size to -54 kD and increased the pl
to between 5.8 and 6.6 . The acidic charge of the IgA-R thus could be due in part
to the post-translational addition of sialic acid (-20 residues) to the molecule.
Removal of N-linked oligosaccharides from the 60-kD FcciR consistently yielded two
bands of 32 and 36 kD on both cell types in experiments using different concentra-
tions ofN-glycanase. The fact that resistantN-linked oligosaccharides have notbeenreported (66) argues against a partial deglycosylation. Rather, the appearance of
two deglycosylated IgA-R bands with a 4-kD difference raises two interesting possi-
bilities: (a) an allelic polymorphism of this FCaR; or (b) two different glycosylated
FcciR isoforms with similar electrophoretic mobilities. An analogous situation has
been reported for the FcyR III in which two bands are obtained after complete
deglycosylation (9, 13, 43, 45, 46; see Fig. 8). Polymorphic FcyR III are observed
on granulocytes, where two allelic forms, NA-1 and NA-2, can be distinguished by
human alloantisera and specific mAbs (67). Two single nucleotide changes in the
extracellular domain of the granulocyte FcyR III gene account for allelic forms of
the molecule, with the loss of an 0-linked glycosylation site in the NA-1 allele (13).
Thus atwo-band pattern occurs in SDS-PAGE analysis afterN-glycanase treatment
of the granulocyte FcyR III from donors heterozygous for NA-1 and NA-2 alleles
(13, 46). Thesimilarity between the two-band patterns observed for the60-kD FCaR
and for the FcyR III after N-glycanase digestion may suggest that these molecules
share the same type of gene complexity. However, it is noteworthy that there is a
difference between FcctR and FcyR III with regard to their attachment to the cell
membrane. The FCaR described here is PI-PLC resistant on all cell sources exam-
ined, suggesting thepresence oftransmembranesegments, whereas both GPI-linked
and transmembrane forms of FcyR III have been identified on granulocytes and
NK cells, respectively (12, 13). The possibility for two FcaR isoforms could be ex-
plained by alternative RNA splicing (e.g., murine FcyR 11 9 gene) (68), by post-
transcriptional changes in mRNA processing, as described forapolipoprotein B (69),
or by two distinct genes.
We conclude that monocyte/macrophages and granulocytes express a novel FCaR.
The production of mAbs specific for this FcaR and identification of the encoding
gene(s) will allow further definition of this receptor and exploration of the tissue-
specific nature of this receptor molecule.
Summary
In these studies, we characterize an Fc receptor (FcR) for IgA that is present on
human granulocytes, monocyte/macrophages, and their corresponding cell lines.
Receptor expression appears to be constitutive but can be selectively upregulated
on monocyte cell lines by stimulation with a phorbol ester and polymeric IgA. Both
the induction requirements and ligand specificity of the IgA receptor differ from
the IgG receptors, FcyR I, II, and III, that are also expressed on monocytes and
granulocytes. IgA binding to the cell surface receptor is mediated via the Fca re-
gion. The FcceR is a heterogenously charged, N60-kD molecule with an isoelectric
pointof 4.5-5.6 that binds monomeric or polymericIgAl and IgA2 molecules. This
transmembrane glycoprotein appears to be composed of32- and 36-kD protein cores
with multiple N-linked carbohydrate moieties. We conclude that this FcaR represents
a novel member of the FcR family that may have a distinctive role in host defense.
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